Beijing Tong Ren Tang Chinese Medicine Company Limited (TQR.F)
| Previous close | 1.1000 |
| Open | 1.1000 |
| Bid | 1.0700 x 780000 |
| Ask | 1.1600 x 780000 |
| Day's range | 1.1000 - 1.1000 |
| 52-week range | 1.0300 - 1.7200 |
| Volume | |
| Avg. volume | 68 |
| Market cap | 927.196M |
| Beta (5Y monthly) | 0.38 |
| PE ratio (TTM) | 13.75 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 0.04 (3.58%) |
| Ex-dividend date | 12 June 2024 |
| 1y target est | N/A |
- Simply Wall St.
Exploring Top Dividend Stocks In Hong Kong June 2024
As of June 2024, the Hong Kong market faces challenges, notably marked by a 2.84% drop in the Hang Seng Index amidst broader global economic uncertainties and specific regional growth headwinds. This backdrop makes it particularly pertinent for investors to consider the stability offered by dividend-paying stocks, which can provide potential income and a degree of protection in volatile markets. In this context, understanding what constitutes a resilient dividend stock becomes crucial;...
- Simply Wall St.
Three High Yield Dividend Stocks In Hong Kong Offering Up To 8.4%
Amid a generally positive backdrop in global markets, with indices like the Hang Seng showing notable gains, investors are increasingly attentive to opportunities within Hong Kong's dividend stock arena. In this context, understanding the characteristics that define a robust dividend stock is crucial, especially in a market buoyed by recovery optimism and solid holiday spending figures.
- Reuters
UPDATE 1-Chinese listed firms used endangered animal parts as ingredients -report
Three listed Chinese drugmakers, whose investors include or use some of the world's biggest banks, used parts of endangered animals as ingredients in their products, an environmental group said in a report published Monday. The London-based Environmental Investigation Agency (EIA) urged investors in Beijing Tong Ren Tang group, Tianjin Pharmaceutical group and Jilin Aodong Pharmaceutical Group to divest their stakes. Beijing Tong Ren Tang and Tianjin Pharmaceutical group did not respond to Reuters' emails or calls seeking comment.
